Bank skeptical about Novo Nordisk share price – requires USD 40bn a year in obesity drug sales

Berenberg is baffled by Novo Nordisk's share price, which according to the Germany-based bank, would require an almost impossible sales volume for obesity drug Wegovy.

Photo: Novo Nordisk/PR

A new analysis conducted by German bank Berenberg has left it with questions about Novo Nordisk's share price, which currently reflects a market expectation that its obesity drug Wegovy will acheive peak sales of USD 40bn (DKK 250bn) a year.

Danish financial daily Børsen reports that according to Berenberg, the products that the pharmaceutical company currently has on the market account for USD 67 (DKK 422) per share. This is in line with expectations for those products, the bank finds.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs